Business
Longeveron® to Attend BIO International Convention 2025
Focus on potential partnership and strategic opportunities for the Company’s stem cell therapy program for Alzheimer’s diseaseRecent Type B meeting with FDA provided alignment on a planned single, pivotal Phase 2/3 clinical trial, which if positive, would be acceptable for Biological License Application (BLA) submission for Alzheimer’s diseaseInitiation of planned single, pivotal Phase 2/3 clinical trial in mild Alzheimer’s disease anticipated in 2H 2026, contingent upon obtaining non-dilutive f
About this update from Longeveron Inc.
[{"type":"image","alt":"Longeveron","displaySize":"","headline":null,"caption":"Longeveron","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":56,"url":"https://media.zenfs.com/en/globenewswire.com/7020f3e4e4ad01a05af1150b74d0406a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/.X2J.blw.0f9XkdGnRbwAQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc4O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/7020f3e4e4ad01a05af1150b74d0406a","width":300,"height":56}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Focus on potential partnership and strategic opportunities for the Company’s stem cell therapy program for Alzheimer’s disease","length":126,"tagName":"p"}]},{"val":[{"type":"text","content":"Recent Type B meeting with FDA provided alignment on a planned single, pivotal Phase 2/3 clinical trial, which if positive, would be acceptable for Biological License Application (BLA) submission for Alzheimer’s disease","length":219,"tagName":"p"}]},{"val":[{"type":"text","content":"Initiation of planned single, pivotal Phase 2/3 clinical trial in mild Alzheimer’s disease anticipated in 2H 2026, contingent upon obtaining non-dilutive funding and/or partnering support","length":187,"tagName":"p"}]},{"val":[{"type":"text","content":"Results from the Phase 2a clinical trial (CLEAR MIND) evaluating laromestrocel as a potential treatment for Alzheimer’s disease were published in the peer reviewed journal Nature Medicine","length":187,"tagName":"p"}]},{"val":[{"type":"text","content":"Laromestrocel is, to Company’s knowledge, the first cellular therapeutic candidate to receive FDA Regenerative Medicine Advanced Therapy (RMAT) designation for Alzheimer’s disease","length":179,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":898,"olType":false},{"type":"text","content":"MIAMI, May 20, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that the Company will participate in the BIO International Convention taking place June 16-19, 2025 at the Boston Convention & Exhibition Center.","length":387,"tagName":"p"},{"type":"text","content":"At the conference, members of the Longeveron management team will host meetings with global pharmace...